ABSTRACT
triphosphate-dependent phosphoglycoprotein that is located in the cell membranes of numerous tissues, is responsible for the efflux of colchicine across membranes, including within enterocytes of the intestine. P-gp plays a predominant role in the incomplete absorption of colchicine (mean absolute bioavailability is approximately 45%), the enterohepatic recirculation that occurs as evidenced by secondary peak plasma concentrations and for many potential drug-drug interactions (e.g., cyclosporin) [5, 6] .
Colchicine also undergoes hepatic biotransformation by cytochrome 3A4 (CYP3A4) to form three minor metabolites (2-O-demethylcolchicine, 3-O-demethylcolchicine, and 10-O-demethylcolchicine) that account for less than 5% of the parent compound in human plasma [4] . CYP3A4 inhibition of colchicine by certain drugs (e.g., macrolides, statins) has the potential to induce colchicine toxicity by dual modulation of both P-gp and CYP3A4 [6] .
There is little information on the potential effect of age, gender, or race on the pharmacokinetics of colchicine. A published study investigated the pharmacokinetics of colchicine in six healthy young men and four elderly women after single-dose administration intravenously (i.v.) (0.5 mg in young men and 1 mg in elderly women) and orally (1 mg in each group) [8] . Mean absolute bioavailability was similar in the young men and elderly women (44% vs. 45%, respectively), whereas peak plasma concentration (C max ) was approximately twofold higher in the elderly women compared with the young men (5.5 vs. 12 ng/mL). Following i.v. administration, the volume of distribution at steady state (4.2 vs. 2.9 L/kg) and total body clearance (10.5 vs. 5.5 L/h) were reduced in the elderly women.
INTRODUCTION
The prevalence of gout is increasing due to various factors, including the aging population and dietary/lifestyle changes [1, 2] . The National Health and Nutrition Examination Survey (NHANES) estimated the prevalence of gout in the US population between 2007 and 2008 to be 8.3 million adults (≥20 years of age), affecting 6.1 million men (5.9% of the population) and 2.2 million women (2.0% of the population) [3] .
The overall prevalence of gout has increased from 2.7% (NHANES III, 1988 -1994 ) to 3.9% (NHANES, 2007 (NHANES, -2008 [3] .
Colchicine 0.6 mg is indicated for the prophylaxis and treatment of acute gout attacks in adults and the treatment of familial Mediterranean fever in adults and children 4 years of age and older [4] . There is limited information on the effect of age on the pharmacokinetics of colchicine.
Colchicine binds to β-tubulin heterodimers that comprise microtubules, disrupting the cytoskeleton and inducing various signaling pathways and cellular events, eventually resulting in its anti-inflammatory mechanism of action in the treatment of gout [5, 6] .
Although the exact mechanism has not been completely elucidated, colchicine inhibits the inflammasome complex in neutrophils and monocytes, interfering with the activation of the proinflammatory cytokine interleukin-1β [7] . The ubiquitous nature of microtubules contributes to the apparent volume of distribution (Vd/F) of colchicine, which greatly exceeds total body volume, and the slow dissociation half-life (T 1/2 ) of the tubulin-colchicine complex (20-30 hours) contributes to the prolonged plasma elimination half-life [5] . P-glycoprotein (P-gp), the adenosine 
Study Design
The study protocol received ethics committee approval (Novum Independent Institutional Review Board). All subjects provided written informed consent before study participation, which was conducted in accordance with the US Code of reported in the US prescribing information [4] , reviews [5, 9] , and studies in young subjects [10, 11] , but the potential effect of age per se on drug disposition of this formulation has not been formally investigated until now. The objective of this study was to compare the pharmacokinetics of colchicine following the oral administration of a single 0.6 mg tablet of the approved colchicine formulation when given to young (18-30 years of age) and elderly (≥60 years of age) healthy subjects following an overnight fast. Subjects were advised that they could withdraw from the study at any time for any reason. All treatment-emergent adverse events (AEs)
METHODS

Subjects
were recorded (coded using MedDRA version 12.0 adverse event dictionary) and were graded by intensity (mild, moderate, or severe) and relationship to the study drug (unlikely, possible, or probable) by the investigator.
Pharmacokinetic Measurements
Venous blood samples (6 mL in prechilled EDTA 
Statistical Analysis
Descriptive statistics (mean ± SD) were used Post-hoc analysis of differences in race and gender (n = 38) was also performed.
RESULTS
Baseline demographic and clinical characteristics
for the 38 subjects (20 young and 18 elderly; 20 women and 18 men; 14 African American, 15 white, and 9 "other") included in the statistical analysis are summarized in Table 1 .
Elderly subjects in this study had a median age of 62 years and a mean age of 62.8 ± 2.83 years.
No subjects older than 70 years were enrolled in the study. The age groups were balanced for weight and body mass index. There were significant differences in mean age (P < 0.001) and CrCl (P < 0.001) between the young and elderly groups. There was a statistically significant difference (P < 0.001) in CrCl between age groups (132 ± 23.2 mL/min for young vs. 87.0 ± 17.9 mL/min for elderly subjects). Race was predominantly black among the young subjects and white among the elderly subjects, with a significant between-group difference (P < 0.001). All 38 subjects were evaluated for safety.
Mean plasma concentration-time profiles for colchicine in the young and elderly subjects are graphically presented in Fig. 1 . The arithmetic mean pharmacokinetic parameters for colchicine in the young and elderly groups are summarized in Table 2 . Statistical comparisons revealed no statistically significant (P < 0.05) differences between the age groups for any of the colchicine pharmacokinetic parameters.
The relationship between exposure to colchicine (AUC) and CrCl is presented graphically in Fig. 2 .
A trend for higher colchicine systemic exposure with decreasing renal function (as measured by CrCl) was seen; however, the magnitude of the differences was small and not clinically meaningful.
With regard to gender, there was a significant difference (P < 0.05) in AUCs; however, the mean Table 2 Arithmetic mean pharmacokinetic parameters by age group for colchicine administered as a single 0.6-mg tablet to healthy subjects (n = 38) ANOVA comparisons by gender showed slightly higher C max (2.76 vs. 2.38 ng/mL) and AUC (26.2 vs. 21.7 ng/h/mL) in female subjects, differences that were not statistically significant (P > 0.05). Furthermore, no significant gender differences were seen in T max , AUC, CL/F, Vd/F, or T 1/2 . There were no significant differences in colchicine pharmacokinetic parameters between the racial groups.
Parameter
A total of 15 of the 38 subjects reported 22 treatment-emergent AEs, with seven in the young group and eight in the elderly group (Table 3) .
None of the AEs was considered serious. All 22 AEs were classified as mild in intensity and resolved spontaneously before study completion.
The AE relationship to drug was considered unlikely (n = 11) or possible (n = 11). The most frequent AEs were increased blood pressure and 38.9% elderly subjects [n = 7]) [4] . For the occurrence of increased blood pressure, it was determined that a relationship to study drug in this study was unlikely.
DISCUSSION
The study sought to compare the relative Single-dose colchicine 0.6 mg was well tolerated in young and elderly healthy subjects.
There were no clinically meaningful differences in colchicine pharmacokinetic parameters (i.e., C max , AUC, T 1/2 , and CL/F) between young and elderly healthy subjects, including those with mild renal impairment. In addition, there were no statistically significant differences (P < 0.05) observed in the comparisons of the pharmacokinetic parameters by race or gender. Although the study was not designed to examine gender or race differences in colchicine pharmacokinetics, comparisons were performed on the pooled data across the two age groups by gender and race.
CONCLUSION
The only previous recommendation for colchicine dosing was reported by Terkeltaub [12] , who suggested that the recommended maintenance dose of colchicine should be reduced by half in patients 70 years of age or older. These data were empirical and not based on actual study results.
In this study, the lack of any clinically meaningful differences in colchicine 
